Early treatment of ATTR-CM with tafamidis increases survival
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening rare disease caused by unstable transthyretin proteins that misfold and aggregate into insoluble amyloid fibrils that deposit in the heart and other organs of the body. Tafamidis, a transthyretin stabilizer, is the first disease-modifying therapy approved for ATTR-CM. Clinical Assistant Professor Khoo Chun Yuan, Consultant Cardiologist at the National Heart Centre Singapore, discusses the importance of early diagnosis and treatment of ATTR-CM patients.
Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in